Allergan launches innovative injectable treatment designed to improve skin quality for up to 9 months in UAE

Hyaluronic Acid (HA) gel designed to improve skin’s smoothness (absence of fine lines), hydration and elasticity for up to nine months with just one treatment

Global research shows more than 50% women say appearance of skin contributes to their outer beauty[1]

United Arab Emirates, Dubai: Allergan, a leading global biopharmaceutical company, announced today the launch of its new injectable treatment designed to improve skin quality and lasts up to nine months with just one treatment session. The treatment uses the unique patented VYCROSS^® technology.

The new injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment.  

The treatment has demonstrated efficacy in improving skin quality during a clinical trial involving 131 patients. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. It further enhances patient comfort by eliminating the need for multiple treatments.

Ramsey Morad, Allergan’s Vice President for India, Middle East and Africa said, “The launch of this new treatment defines Allergan’s entrance into the skin quality category – an area that we know is set to experience huge growth over the next few years in the UAE and the wider region, and with a treatment module designed to last up to nine months with just one treatment.”

“This demonstrates our ongoing commitment to delivering medical aesthetics treatment that physicians and their patients really want, that is convenient for patients and doctors, and of high quality in its results and safety,” added Morad.

Moreover, Dr. Khalid Al Awadi, Consultant Plastic and Hand Surgeon at Acacia Medical Centre also noted, “The new technology reflects a real patient need for a treatment that delivers a healthy-looking glow providing results from just one treatment. We believe that great skin can have a profound impact on patients’ everyday lives as smooth, radiant, hydrated skin from within hugely improves self-confidence.”

In the UAE, consumers spent US$2.1 billion on beauty and personal care in 2016 according to EMI, this set to rise to US$2.7 billion by 2020.[2] 

“Allergan is strongly committed to the health, safety and well-being of the practitioners and patients who put their trust in our products, as part of the company’s ongoing commitment to medical education,” noted Morad.

-Ends-

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com. 

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

[1] New Global Research Shows Changing Attitude Toward Beauty as Women Seek Confidence Over Youth | https://www.newswire.ca/news-releases/new-global-research-shows-changing-attitude-toward-beauty-as-women-seek-confidence-over-youth-600240911.html 

[2] UAE consumers spent US$2.1 billion on beauty and personal care in 2016 | https://www.emirates247.com/news/emirates/uae-consumers-spent-us-2-1bn-on-beauty-and-personal-care-in-2016-2017-02-03-1.647586 

© Press Release 2018